Results 101 to 110 of about 22,142 (188)

Ibrutinib oral suspension bioavailability and compatibility for optimal enteral administration route

Therapeutic Advances in Hematology
Background: Ibrutinib is the only Bruton tyrosine kinase inhibitor (BTKi) with once-daily oral capsule, tablet, and oral suspension formulations approved in the United States across indications of chronic lymphocytic leukemia/small lymphocytic lymphoma ...
Jonas Paludo, Lisa Nodzon, Xavier Woot de Trixhe, Michelle Pacia, Heena Mavani, Harisha Atluri, Thomas J. Huemann, Jessica Shelly, Yemin Liu, Shayna Sarosiek   +9 more
doaj   +1 more source

Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma

Frontiers in Hematology
BackgroundMantle cell lymphoma is usually characterized by an aggressive and recurrent course. Clinical trials and real-world series have demonstrated clinical benefits with the use of ibrutinib as a second-line treatment, compared to later relapses ...
Catarina Fernandes, Rita Costa e Sousa, Pedro Santos, Cátia Almeida, Adriana Roque, Ana Luísa Pinto, Joaquim Monteiro, Anabela Neves, Maria João Ramos, Rita Coutinho, Rita Coutinho, Rita Coutinho, Filipa Mousinho, Mariana Leal Fernandes, Margarida Badior, Cristina João, Cristina João, Sónia Leocádio, Ana Luísa Tomé, Margarida Carrolo, Sara Dias, Maria Gomes da Silva, João Paulo Fernandes   +22 more
doaj   +1 more source

The role of ibrutinib in Waldenström macroglobulinemia

, 2018
Introduction: Waldenström macroglobulinemia (WM) is an uncommon incurable B-cell lymphoma characterized by the presence lymphoplasmacytic cells in the bone marrow.
Gavriatopoulou, M., Terpos, E., Dimopoulos, M.A., Kastritis, E.   +3 more
core   +1 more source

Ibrutinib causes repression of lymphoma growth.

, 2019
(A) T2 weighted MRI scans showing spontaneous regression and progression over the course of treatment with vehicle. (B) T2 weighted MRI scans showing exemplar slices from animals responding to ibrutinib or with stable disease.
Rebecca L. Allchin (6623315), Simon D. Wagner (530388), Thomas Keane (225299), Michael E. Kelly (3285351), Matthew J. Ahearne (4730571), Anthony G. Doran (6623321), Sami Mamand (6623318)   +6 more
core   +1 more source

Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes

Research
Background: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF).
Yukun Li, Xinmeng Liu, Rong Lin, Xiaodong Peng, Xuesi Wang, Fanchao Meng, Shuqi Jin, Wenhe Lv, Xiaoying Liu, Zhuohang Du, Songnan Wen, Rong Bai, Yanfei Ruan, Hao Zhou, Rongjun Zou, Ribo Tang, Nian Liu   +16 more
doaj   +1 more source

Monocyte-to-macrophage switch reversibly impaired by Ibrutinib.

, 2019
Ibrutinib is increasingly adopted for treating lymphoid malignancies. While growing amounts of data pile up about Ibrutinib mechanism of action on neoplastic B cells, little is known about its impact on other immune cells. Here we investigated the effect
Montresor, Alessio, Laudanna, Carlo, Ferrarini, Isacco, Vinante, Fabrizio, Rigo, Antonella   +4 more
core   +1 more source

Abstract 5218: Breast cancer resistance protein (ABCG2) and P-glycoprotein (ABCB1) transport ibrutinib and may restrict its oral availability and brain accumulation, whereas CYP3A4 limits ibrutinib oral availability

, 2017
Introduction: Ibrutinib (Imbruvica, PCI-32765) is an orally administered tyrosine kinase inhibitor (TKI) approved by the FDA in 2014 for treatment of B-cell malignancies.
Els Wagenaar, Alfred Schinkel, Jos Beijnen, Stephanie van Hoppe, Rolf Sparidans, Gert-Jan Rood   +5 more
core   +1 more source

Geta efliraðir umritunar miðlað ibrutinib lyfjaþoli í Waldenström risaglóbúlíndreyra?

Waldenström macroglobulinemia (WM) is a rare, indolent, and incurable B-cell malignancy. Treated with ibrutinib to suppress symptoms, the tumour is susceptible to developing ibrutinib resistance as they need constant treatment throughout their lifespan ...
Björgvin Ægir Elisson 2000-
core  

Gene expression analysis after BTK and PI3Kδ inhibitor treatment in chronic lymphocytic leukemia identifies cell-surface CXCR4 as a synergistic target for combinatorial therapy. [PDF]

Hemasphere
Mladonicka Pavlasova G, Sandova V, Ondrisova L, Seda V, Pavelkova P, Filip D, Hlavac K, Vecera J, Pospisilova S, Panovska A, Fernandes SM, Doubek M, Brown JR, Mraz M.   +13 more
europepmc   +1 more source

Risk stratification of ibrutinib toxicity co-administered with triazole antifungals: insights from real-world pharmacovigilance and clinical evidence. [PDF]

Front Med (Lausanne)
Li S, Li Z, Wang S.
europepmc   +1 more source